261 related articles for article (PubMed ID: 31111437)
1. Pembrolizumab-Induced Thyroiditis.
Imblum BA; Baloch ZW; Fraker D; LiVolsi VA
Endocr Pathol; 2019 Jun; 30(2):163-167. PubMed ID: 31111437
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
4. Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report.
Jabkowski J; Loidl A; Auinger B; Kehrer H; Sepp N; Pichler R
Front Immunol; 2021; 12():606056. PubMed ID: 34220792
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
7. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
8. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
Zwirska-Korczala K; Berdowska A; Jochem J; Sitkiewicz A; Birkner E; Polaniak R; Jedrzejowska-Szypułka H; Korzonek-Szlacheta I
J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
[TBL] [Abstract][Full Text] [Related]
9. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P
Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083
[TBL] [Abstract][Full Text] [Related]
10. Graves' disease in a mediastinal mass presenting after total thyroidectomy for nontoxic multinodular goiter: a case report.
Cunha FM; Rodrigues E; Oliveira J; Saavedra A; Vinhas LS; Carvalho D
J Med Case Rep; 2016 Mar; 10():70. PubMed ID: 27029843
[TBL] [Abstract][Full Text] [Related]
11. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab-Induced Thyroiditis and Colitis-Presentation and Resolution on Serial FDG PET/CT.
Nawwar AA; Searle J; Lyburn ID
Clin Nucl Med; 2021 Feb; 46(2):e121-e122. PubMed ID: 32969909
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of Graves' disease and unilateral functioning Struma ovarii: a case report.
Sitasuwan T; Hanamornroongruang S; Peerapatdit T; Thongtang N
BMC Endocr Disord; 2015 Nov; 15():68. PubMed ID: 26530865
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab Exacerbates Thyroid Diseases Shown on FDG PET/CT.
Wang X; Wang J; Yang X; Zhao H; Huo L
Clin Nucl Med; 2020 Dec; 45(12):1010-1012. PubMed ID: 32910056
[TBL] [Abstract][Full Text] [Related]
15. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
Orlov S; Salari F; Kashat L; Walfish PG
J Clin Endocrinol Metab; 2015 May; 100(5):1738-41. PubMed ID: 25751110
[TBL] [Abstract][Full Text] [Related]
16. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
Edahiro R; Ishijima M; Kurebe H; Nishida K; Uenami T; Kanazu M; Akazawa Y; Yano Y; Mori M
Thorac Cancer; 2019 May; 10(5):1276-1279. PubMed ID: 30964601
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hemiagenesis with postpartum silent thyroiditis.
Nakamura S; Isaji M; Ishimori M
Intern Med; 2004 Apr; 43(4):306-9. PubMed ID: 15168773
[TBL] [Abstract][Full Text] [Related]
18. [Atypical subacute thyroiditis in combination with Grave's disease:Diagnostic difficulties in a case report].
Koutouridou E; Planck T; Uddman E; Lantz M
Lakartidningen; 2018 Apr; 115():. PubMed ID: 29664539
[TBL] [Abstract][Full Text] [Related]
19. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Mehnert JM; Varga A; Brose MS; Aggarwal RR; Lin CC; Prawira A; de Braud F; Tamura K; Doi T; Piha-Paul SA; Gilbert J; Saraf S; Thanigaimani P; Cheng JD; Keam B
BMC Cancer; 2019 Mar; 19(1):196. PubMed ID: 30832606
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors.
Lei M; Michael A; Patel S; Wang D
J Oncol Pharm Pract; 2019 Sep; 25(6):1402-1411. PubMed ID: 30782080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
